Shopping Cart 0
Cart Subtotal
AED 0

Nightstar Therapeutics PLC (NITE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Nightstar Therapeutics PLC (Nightstar Therapeutics), formerly Nightstar Therapeutics Ltd, is a clinical-stage gene therapy company. The company focus on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. Its lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia; and NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease. The company also develops NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy; and NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. It develops retinal gene therapies for patients suffering from rare inherited retinal disease. Nightstar Therapeutics is headquartered in London, the UK.

Nightstar Therapeutics PLC (NITE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Nightstar Therapeutics PLC, Medical Devices Deals, 2012 to YTD 2018 9

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

NightstaRx Raises USD45 Million in Series C Financing 11

NightstaRx Raises USD35 Million in Series B Financing Round 12

Nightstar Raises Additional USD8.2 Million in Venture Financing Round 13

NightstaRx Raises USD 19.8 Million In Venture Financing 14

Licensing Agreements 15

Nightstar Therapeutics Enters into Licensing Agreement with Oxford University Innovation 15

NightstaRx Enters into Licensing Agreement with Oxford University 16

NightstaRx Expands Licensing Agreement with Isis Innovation 17

NightstaRx Enters into Licensing Agreement with Oxford University Innovation 18

Equity Offering 19

Nightstar Therapeutics Raises USD86.3 Million in Public Offering of American Depository Shares 19

Nightstar Therapeutics Raises USD86.3 Million in IPO 21

Nightstar Therapeutics PLC-Key Competitors 23

Nightstar Therapeutics PLC-Key Employees 24

Nightstar Therapeutics PLC-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

Aug 13, 2018: Nightstar Therapeutics reports second quarter 2018 financial results and business highlights 26

Jun 06, 2018: Nightstar Therapeutics Reports First Quarter 2018 Financial Results 28

Apr 03, 2018: Nightstar Therapeutics Reports 2017 Financial Results and Business Highlights 29

Corporate Communications 31

Sep 13, 2018: Nightstar Therapeutics names Paula Cobb as Board Director 31

Product News 32

03/19/2017: NightstaRx Commences first Phase I/II Gene Therapy Clinical Trial for Patients with X-Linked Retinitis Pigmentosa 32

Clinical Trials 33

Mar 05, 2018: Nightstar Therapeutics Announces Initiation of STAR Phase 3 Registrational Trial for NSR-REP1 in Choroideremia 33

Other Significant Developments 34

Oct 09, 2018: Gene therapy breakthrough in treating a rare form of blindness 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35


List Of Figure

List of Figures

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Nightstar Therapeutics PLC, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Nightstar Therapeutics PLC, Deals By Therapy Area, 2012 to YTD 2018 8

Nightstar Therapeutics PLC, Medical Devices Deals, 2012 to YTD 2018 9

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

NightstaRx Raises USD45 Million in Series C Financing 11

NightstaRx Raises USD35 Million in Series B Financing Round 12

Nightstar Raises Additional USD8.2 Million in Venture Financing Round 13

NightstaRx Raises USD 19.8 Million In Venture Financing 14

Nightstar Therapeutics Enters into Licensing Agreement with Oxford University Innovation 15

NightstaRx Enters into Licensing Agreement with Oxford University 16

NightstaRx Expands Licensing Agreement with Isis Innovation 17

NightstaRx Enters into Licensing Agreement with Oxford University Innovation 18

Nightstar Therapeutics Raises USD86.3 Million in Public Offering of American Depository Shares 19

Nightstar Therapeutics Raises USD86.3 Million in IPO 21

Nightstar Therapeutics PLC, Key Competitors 23

Nightstar Therapeutics PLC, Key Employees 24

Nightstar Therapeutics PLC, Subsidiaries 25

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Nightstar Therapeutics PLC, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Nightstar Therapeutics PLC (Nightstar Therapeutics), formerly Nightstar Therapeutics Ltd, is a clinical-stage gene therapy company. The company focus on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. Its lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia; and NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease. The company also develops NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy; and NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. It develops retinal gene therapies for patients suffering from rare inherited retinal disease. Nightstar Therapeutics is headquartered in London, the UK.

Nightstar Therapeutics PLC (NITE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Nightstar Therapeutics PLC, Medical Devices Deals, 2012 to YTD 2018 9

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

NightstaRx Raises USD45 Million in Series C Financing 11

NightstaRx Raises USD35 Million in Series B Financing Round 12

Nightstar Raises Additional USD8.2 Million in Venture Financing Round 13

NightstaRx Raises USD 19.8 Million In Venture Financing 14

Licensing Agreements 15

Nightstar Therapeutics Enters into Licensing Agreement with Oxford University Innovation 15

NightstaRx Enters into Licensing Agreement with Oxford University 16

NightstaRx Expands Licensing Agreement with Isis Innovation 17

NightstaRx Enters into Licensing Agreement with Oxford University Innovation 18

Equity Offering 19

Nightstar Therapeutics Raises USD86.3 Million in Public Offering of American Depository Shares 19

Nightstar Therapeutics Raises USD86.3 Million in IPO 21

Nightstar Therapeutics PLC-Key Competitors 23

Nightstar Therapeutics PLC-Key Employees 24

Nightstar Therapeutics PLC-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

Aug 13, 2018: Nightstar Therapeutics reports second quarter 2018 financial results and business highlights 26

Jun 06, 2018: Nightstar Therapeutics Reports First Quarter 2018 Financial Results 28

Apr 03, 2018: Nightstar Therapeutics Reports 2017 Financial Results and Business Highlights 29

Corporate Communications 31

Sep 13, 2018: Nightstar Therapeutics names Paula Cobb as Board Director 31

Product News 32

03/19/2017: NightstaRx Commences first Phase I/II Gene Therapy Clinical Trial for Patients with X-Linked Retinitis Pigmentosa 32

Clinical Trials 33

Mar 05, 2018: Nightstar Therapeutics Announces Initiation of STAR Phase 3 Registrational Trial for NSR-REP1 in Choroideremia 33

Other Significant Developments 34

Oct 09, 2018: Gene therapy breakthrough in treating a rare form of blindness 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35


List Of Figure

List of Figures

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Nightstar Therapeutics PLC, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Nightstar Therapeutics PLC, Deals By Therapy Area, 2012 to YTD 2018 8

Nightstar Therapeutics PLC, Medical Devices Deals, 2012 to YTD 2018 9

Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

NightstaRx Raises USD45 Million in Series C Financing 11

NightstaRx Raises USD35 Million in Series B Financing Round 12

Nightstar Raises Additional USD8.2 Million in Venture Financing Round 13

NightstaRx Raises USD 19.8 Million In Venture Financing 14

Nightstar Therapeutics Enters into Licensing Agreement with Oxford University Innovation 15

NightstaRx Enters into Licensing Agreement with Oxford University 16

NightstaRx Expands Licensing Agreement with Isis Innovation 17

NightstaRx Enters into Licensing Agreement with Oxford University Innovation 18

Nightstar Therapeutics Raises USD86.3 Million in Public Offering of American Depository Shares 19

Nightstar Therapeutics Raises USD86.3 Million in IPO 21

Nightstar Therapeutics PLC, Key Competitors 23

Nightstar Therapeutics PLC, Key Employees 24

Nightstar Therapeutics PLC, Subsidiaries 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Nightstar Therapeutics PLC, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.